Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Marina, Etcheverrigaray"'
Autor:
Eduardo Federico Mufarrege, Lucía Carolina Peña, Marina Etcheverrigaray, Anne S. De Groot, William Martin
Publikováno v:
Heliyon, Vol 9, Iss 3, Pp e14670- (2023)
For decades, recombinant human interferon alpha (rhIFN-α2b) has been used to treat emerging and chronic viral diseases. However, rhIFN-α2b is immunogenic and has a short in vivo half-life. To solve these limitations, two long-lasting hyperglycosyla
Externí odkaz:
https://doaj.org/article/9ec60d2ab57e47fd9ae00c3c82af6b1f
Autor:
Marcos Oggero, Natalia Ceaglio, María Jesús Leopold, Eduardo Federico Mufarrege, Marina Etcheverrigaray, Ricardo Kratje, Agustina Gugliotta
Publikováno v:
Pharmaceutical Research. 38:37-50
IFN4N is a glycoengineered version of recombinant human interferon alpha 2 (rhIFN-α2) that was modified to exhibit four N-glycosylation sites. It shows reduced in vitro specific biological activity (SBA) mainly due to R23 mutation by N23. However, i
Autor:
Juan Manuel Battagliotti, Diego Fontana, Marina Etcheverrigaray, Ricardo Kratje, Claudio Prieto
Publikováno v:
Vaccine Design ISBN: 9781071618837
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc5baa18a1c062b8d69311e906c81e99
https://doi.org/10.1007/978-1-0716-1884-4_13
https://doi.org/10.1007/978-1-0716-1884-4_13
Autor:
Juan Manuel, Battagliotti, Diego, Fontana, Marina, Etcheverrigaray, Ricardo, Kratje, Claudio, Prieto
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2410
Vaccination still represents the most efficient and inexpensive strategy in the control of hepatitis B virus (HBV) infection. However, about 10% of the population vaccinated with the current S yeast-derived vaccine fail to induce an adequate immune r
Autor:
Marcelo Calderón, Luis Marcelino Gugliotta, Agustina Gugliotta, Cecilia Ines Alvarez Igarzabal, Marina Etcheverrigaray, Julio César Cuggino, Matías Luis Picchio, Ludmila Irene Ronco, Roque Javier Minari, Milagros Bürgi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Nanomedicine for cancer therapy is a successful tool to diminish the side effect of chemotherapeutics such as paclitaxel (PTX). In this regard, Abraxane®, a human serum albumin (HSA)-based nanomedicine system has shown lesser side effects than Taxol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cea50f4eabfc38861877a28971cbbd3
https://linkinghub.elsevier.com/retrieve/pii/S0014305720319546
https://linkinghub.elsevier.com/retrieve/pii/S0014305720319546
Publikováno v:
Journal of virological methods. 286
We carried out an investigation on rabies virus-like particles (RV-VLPs) expressed in HEK293 cells using serum free medium. These RV-VLPs were formulated with two different adjuvants in order to analyse the enhancement of the triggered immune respons
Autor:
Evangelina L. Benizio, Fabricio Chiappini, María Celeste Rodríguez, Claudio Prieto, Ricardo Kratje, Marina Etcheverrigaray, Eduardo Federico Mufarrege
Publikováno v:
Biotechnology and applied biochemistryReferences. 68(2)
In the pharmaceutical industry, the need for high levels of protein expression in mammalian cells has prompted the search for new strategies, including technologies to obtain cells with improved mechanisms that enhance its transcriptional activity, f
Autor:
Marina Etcheverrigaray, Carolina Attallah, Victoria Lozano, María Carla Rodríguez, Marcos Oggero
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Aim: Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus. An immuno-PCR (iPCR) was developed to quantify low amounts of IFN-α in human plasma followed by a deep analysis of the methodologic robustness throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c98b0e842fca026b95e785c144d505be
https://www.future-science.com/doi/10.4155/bio-2019-0225
https://www.future-science.com/doi/10.4155/bio-2019-0225
Autor:
Eduardo Federico Mufarrege, Sofía Inés Giorgetti, Anne S. De Groot, Frances Terry, Marcos Oggero, Natalia Ceaglio, William J. Martin, Marina Etcheverrigaray
Publikováno v:
Clinical Immunology (Orlando, Fla.)
Human interferon alpha (hIFN-α) administration constitutes the current FDA approved therapy for chronic Hepatitis B and C virus infections. Additionally, hIFN-α treatment efficacy was recently demonstrated in patients with COVID-19. Thus, hIFN-α c
Publikováno v:
Journal of Bioscience and Bioengineering. 124:591-598
If cultured in appropriate conditions, such as supplementing culture media with costly cytokines and growth factors, hematopoietic stem/progenitor cells (HSPCs) from different origins have shown to be an adequate source of erythroid cells. This requi